What this page is. A sourced look at endocrine effects of chronic 7-OH and kratom use and the recovery of those systems in the post-acute phase. The evidence base on opioid-induced endocrinopathy is substantial, even where 7-OH-specific data are absent. The page reflects what the actual literature shows; it does not invent timelines or prescribe hormone-replacement protocols. Both men’s and women’s experiences are covered.
Endocrine concerns are appropriately clinical territory. The page describes what’s known so a reader can engage care from a position of knowledge, not from a position of asking permission.
Symptoms readers may not have connected
A list of post-acute symptoms that are commonly endocrine in origin and that many readers months into recovery have not yet linked to the use:
- Low libido or loss of sexual interest
- Erectile dysfunction in men; reduced arousal, lubrication difficulty, or pain with intercourse in women
- Persistent fatigue beyond what early recovery accounts for
- Low motivation and flat mood that overlap with, but aren’t fully explained by, PAWS
- Loss of muscle mass, increased body fat, softer body composition
- Menstrual cycle changes: irregular, absent, or returning differently than before use
- Fertility concerns, either now or anticipated
- Hot flashes and sleep disruption that track with hormone fluctuations
- Brain fog with a hormonal component
- Hormone-related mood swings, sometimes PMS-like or PMDD-like even for readers who didn’t experience these before
Several of these overlap with PAWS symptoms; the endocrine picture and the PAWS picture are connected, not separate. Readers who recognize their experience on this list are not imagining a connection.
The physiology behind it
Chronic activation of mu-opioid receptors suppresses signaling from the hypothalamus, which downregulates the systems below it. Vuong et al., Endocrine Reviews 2010 is the canonical mechanism review covering both animal and human data.
The HPG axis (hypothalamic-pituitary-gonadal). Opioids suppress hypothalamic GnRH release, which lowers pituitary LH and FSH, which reduces testosterone production in men and disrupts cyclical estrogen and progesterone production in women. This is the central mechanism behind libido loss, sexual dysfunction, menstrual changes, and the body-composition and bone-loss effects that follow extended exposure.
The HPA axis (hypothalamic-pituitary-adrenal). Stress-response signaling is dysregulated. Cortisol patterns shift. This contributes to fatigue, sleep disruption, and altered stress response. HPA recovery generally follows its own timeline post-cessation, often resolving over weeks to months.
Prolactin. Often elevated with opioid use, contributing to libido and sexual function effects in both sexes. The case report on a US kratom user (LaBryer et al. 2018) documents this pattern with full normalization after cessation.
Bone metabolism. Chronic opioid-induced hypogonadism is a recognized risk factor for reduced bone mineral density. Coluzzi et al. 2015 summarizes the literature.
For kratom specifically, the evidence is mixed and scope-limited. A Malaysian cross-sectional study of 19 regular male kratom users (Singh et al. 2018) on traditional kratom-leaf preparations at ~76 to 94 mg mitragynine/day found testosterone, FSH, and LH were not impaired. This evidence applies to kratom leaf at moderate doses, not to concentrated 7-OH products, MGM-15, or other synthetics. The LaBryer 2018 US case report, in contrast, documented secondary hypogonadism and elevated prolactin in a frequent kratom user, with both normalizing two months after cessation. The reasonable read: leaf at low-moderate doses may not produce the suppression seen with stronger mu-opioid agonists; concentrated 7-OH products almost certainly do, by the same pharmacology that affects other potent opioids.
For 7-OH specifically, no published human endocrine data exist. Application of the opioid-receptor endocrinology to 7-OH is extrapolation from the broader mu-opioid literature, not from 7-OH-specific studies.
Testing workup
A practical workup. The labs typically ordered when endocrine effects are suspected:
| Test | What it checks | Notes |
|---|---|---|
| Total testosterone | Primary male sex hormone; also relevant for women at lower levels | Multiple morning measurements; single low values aren’t diagnostic |
| Free testosterone | Biologically active fraction | Useful when total is borderline or SHBG is abnormal |
| LH and FSH | Pituitary gonadotropins | Distinguishes primary (high LH/FSH) from secondary (low LH/FSH) hypogonadism |
| Estradiol | Primary female sex hormone; also relevant for men | Cycle-day timing matters for women (days 2–4 for baseline) |
| Progesterone | Ovulation confirmation (women) | Drawn about a week before expected next menses; > 3 ng/mL confirms recent ovulation |
| Prolactin | Often elevated with opioid use | Affects libido and menstrual function |
| TSH | Thyroid screening | Rules out unrelated cause of similar symptoms |
| Morning cortisol | HPA assessment | Sometimes paired with ACTH stimulation if concern is significant |
| SHBG | Sex hormone binding globulin | Helps interpret total-vs-free testosterone discrepancies |
| CMP and CBC | General health baseline | Standard pre-treatment workup |
Testing timing matters. Hormone measurements taken during acute withdrawal or in the first weeks of recovery capture a transient state, not the underlying picture. The Endocrine Society’s 2018 guideline on testosterone therapy in men (Bhasin et al.) emphasizes two morning fasting measurements before diagnosis, noting that 30% of men with an initial low testosterone have a normal repeat measurement. For women, the ASRM 2021 fertility evaluation committee opinion specifies cycle days 2 to 4 for baseline FSH and estradiol.
Where to access testing: primary care, endocrinology, women’s health and men’s health specialists, some telehealth providers. Insurance coverage varies. Direct-pay lab options exist for readers without coverage.
Recovery dynamics
The clearest long-term data come from Tremonti et al. 2026, a 20-year follow-up of a heroin-dependence cohort. Of 123 participants with complete endocrine data, hypogonadism was present in 26.7% of those still using opioids versus 3.3% of those who had achieved sustained opioid-free status. Hypocortisolism was 14.8% in continuing-use versus 0% in opioid-free. The authors conclude opioid-induced endocrine suppression “appears reversible with sustained opioid abstinence,” with the caveat that a small fraction of users do not normalize spontaneously.
Most readers who stop will recover. That’s the headline. The literature on the kinetics (week-by-week recovery curves) is much thinner. Smaller studies and case reports suggest meaningful reversal within weeks to a few months of cessation; the LaBryer US kratom case documented full normalization at two months. Tremonti gives endpoint prevalence at 18 to 20 years; no formal kinetic study has tracked the curve in between. Individual recovery timelines vary widely.
Patterns the literature documents and that readers may experience:
- Early hypersensitivity in some readers. Heightened arousal, intense emotional responses, more vivid sensory experience in the first weeks to months. Real, common, and tends to settle toward a more typical baseline. Don’t pathologize it.
- Rebound spikes. A stretch of unusually strong libido, energy, or mood that doesn’t last. The plateau that follows isn’t backsliding; the system is finding its actual baseline.
- Bloodwork-symptom mismatch in both directions. Some readers have normalized lab numbers while symptoms persist. Others have persistently low numbers with surprisingly intact function. The relationship between hormones on paper and lived experience is real but not 1:1.
- Non-linear symptom recovery. Sleep and mood often improve before sexual function. Body composition may shift before testosterone numbers fully normalize. Cycle regularity may return before associated mood symptoms settle.
- A small fraction does not recover spontaneously. This is where clinical intervention becomes a consideration, covered in the next section.
- “Better than baseline” for some readers, after months. Some report sexual function, mood, or energy stronger than their pre-use baseline once recovery has progressed. Equally, some find their post-recovery normal is just different, not better or worse.
Two readers with identical use histories can have very different recoveries. Age, baseline endocrine status, sleep quality, stress load, other health conditions, mental health, and unknown individual factors all play in. The page does not present any single timeline as “what happens.”
Treatment considerations
For readers whose endocrine systems do not recover spontaneously, replacement therapy is a real option. The page describes the landscape without prescribing.
Testosterone replacement therapy in men is the standard of care for confirmed persistent hypogonadism after appropriate evaluation. Evaluation includes multiple morning testosterone measurements, free testosterone where total is borderline, LH and FSH to distinguish primary from secondary hypogonadism, prolactin, and PSA per current urology guidance. TRT requires ongoing clinical management: labs, monitoring, dose adjustment, and awareness of side effects. The FDA in March 2015 added a Limitation of Use to all testosterone product labels stating they are not approved for age-related testosterone decline; that limitation remains in place. The cardiovascular boxed warning was withdrawn in early 2025 following the TRAVERSE trial (MACE 7.0% vs 7.3% placebo), with new blood-pressure warnings added in its place.
Hormone therapy options in women vary by symptom picture and individual situation. Cycle disruption, persistent low libido, hot flashes, and other hormone-related symptoms can be addressed clinically when they don’t resolve on their own. Specific protocols are individualized and beyond what this page recommends.
Direct-to-consumer “low T clinics” that skip rigorous evaluation, monitor inadequately, or push higher doses than the evidence supports are a category worth skepticism. The standard workup matters; shortcuts to a prescription do not serve the patient well over time.
HPA axis support rarely involves direct medication. Sleep, stress management, and time are the main interventions. The system usually recovers without specific therapy.
The supplement question, briefly
Many readers will encounter heavily marketed “testosterone boosters” (DHEA, tongkat ali, ashwagandha, fenugreek, zinc-magnesium-vitamin-D stacks). The category exists; people use it. Published evidence for these supplements meaningfully raising testosterone in clinically hypogonadal individuals is generally limited; some have modest effects in some populations, others have essentially none. They are not substitutes for clinical evaluation when endocrine effects are persistent. Some interact with medications or have their own side effects. The Vitamins & Supplements page covers the supplement-stack background; this page does not endorse specific protocols.
Men specifically
Most published endocrine-and-opioid literature is male-only or male-dominated, which means men’s evidence is the strongest of any group on this page.
Hypogonadism rates in chronic opioid use. The Daniell 2002 study of 54 men on sustained-action oral opioids for chronic pain found subnormal free testosterone in 56% and subnormal total testosterone in 74%. The Bawor et al. 2014 multi-centre study of methadone maintenance reported mean total testosterone of 100 ng/dL in men on methadone versus 415 ng/dL in controls, roughly a quarter of normal. The Bawor 2015 systematic review and meta-analysis pooled 17 studies and found a mean difference of -164.78 ng/dL in men on chronic opioids versus controls. The dose-response is real: higher methadone doses correlate with lower testosterone.
Sexual function recovery doesn’t track testosterone numbers exactly. Libido and erectile function don’t always recover on the same timeline as testosterone bloodwork, and don’t always recover on the same timeline as each other. Some men see erectile function improve before libido. Some experience early hypersensitivity that settles. Some have bloodwork that looks normal while symptoms persist. Persistent symptoms despite normalized numbers warrant clinical evaluation rather than self-dismissal.
Body composition changes are common during use (loss of muscle mass, increased body fat) and slow to reverse. Resistance training and adequate nutrition support recovery; the timeline is gradual. Some men see composition shift before testosterone numbers fully recover; some see the opposite.
Fertility for men trying to conceive. Opioid use suppresses spermatogenesis; recovery generally restores fertility, but timeline varies. Semen analysis at multiple time points (typically two analyses several months apart) tracks recovery. Men actively trying to conceive should engage a reproductive specialist, especially since some men experience longer recovery here than testosterone numbers alone would suggest.
The TRT decision. When testosterone remains low and symptoms persist after appropriate time off opioids, replacement is a reasonable consideration. The standard evaluation includes multiple morning measurements, free testosterone in borderline cases, LH/FSH to localize the problem, prolactin, ferritin, and PSA. The Endocrine Society 2018 guideline is the canonical reference for clinicians. Shared decision-making matters: TRT is generally lifelong once started, has side effects to monitor (hematocrit, sleep apnea, fertility suppression if not addressed), and is not the right choice for every man with low numbers.
The age question. Men over 50 have lower baseline testosterone naturally. Distinguishing opioid-induced from age-related hypogonadism matters for treatment decisions. Endocrinology evaluation handles this.
Prostate health and TRT. Pre-TRT PSA is part of the routine clinical workup, not optional.
Women specifically
The clinical literature on women is thinner than on men but is genuinely substantive when the right sources are used. The picture below draws on women-specific studies; where evidence is thin or absent for a specific question, the page says so openly.
A foundational reconciliation. Bawor’s 2014 and 2015 meta-analytic work found that opioid use does not significantly suppress testosterone in women the way it does in men. The salient women’s finding is not testosterone but HPG axis disruption manifesting as cycle disruption. Women’s primary sex hormones are estradiol and progesterone, regulated by cyclical LH and FSH signaling. When opioids suppress the hypothalamus, the visible effect in women is menstrual cycle disruption rather than a testosterone collapse.
What opioid use does in women’s HPG axis. The Daniell 2008 study of 47 women on sustained-action oral or transdermal opioids found testosterone, estradiol, and DHEA-S all 48% to 57% lower than controls. LH and FSH were 30% lower in premenopausal women and 70% lower in postmenopausal women. The Abs et al. 2000 study of 44 women on long-term intrathecal opioids found that 21 of 21 premenopausal women had developed amenorrhea or irregular cycles, with ovulation in only one.
Menstrual cycle effects on chronic opioids. The Schmittner et al. 2005 prospective study of 133 women on methadone (70–100 mg) over 25 to 29 weeks documented: 47% had irregular cycles, 28% had regular cycles, 12% experienced cycle restart after prior amenorrhea, 8% had persistent amenorrhea, and 5% had transient amenorrhea. Methadone disrupts cycles substantially but is not uniformly contraceptive. Daniell 2008 documents that menses had often ceased soon after beginning sustained-action opioid therapy in his sample.
Cycle recovery after cessation. This is a literature gap and the page says so directly. No dedicated study has tracked menstrual cycle recovery after opioid cessation in women. Tremonti’s 20-year cohort doesn’t break out women’s cycle data; Schmittner reports during-methadone restoration, not post-cessation. The reasonable read from related work and clinical experience: cycles generally return over weeks to months after cessation, often irregular for a stretch before stabilizing. Variables affecting timeline include duration of use, dose, age, baseline cycle pattern, and overall health. Cycles that have not returned within several months warrant clinical evaluation.
Libido and sexual function in women. The Zamboni et al. 2019 study of 258 women on opioid maintenance treatment (methadone or buprenorphine) found 56.6% had sexual dysfunction by the Arizona Sexual Experience Scale, with no significant difference between methadone and buprenorphine groups overall. The study did not measure hormone levels, so the link is symptomatic rather than mechanism-proven. Pain during intercourse, reduced arousal, decreased lubrication, and difficulty reaching orgasm can occur during use and persist into recovery; these are treatable in clinical contexts when they don’t resolve on their own. As with men, the relationship between hormonal recovery and felt sexual function is real but not 1:1; some women report heightened sensitivity early in recovery, before settling toward a new baseline.
Hormone-related mood symptoms during recovery. As estrogen and progesterone cycling restarts, PMS-like or PMDD-like symptoms can emerge or intensify, sometimes more strongly than the reader experienced pre-use. This tracks hormone fluctuations, not psychology, and usually stabilizes as cycles regularize. Persistent or severe cyclical mood symptoms warrant clinical evaluation; effective treatments exist.
Fertility. Opioid use disrupts ovulation; many women are anovulatory or have irregular ovulation during chronic use (the Abs et al. data above are stark on this). Fertility generally returns with cessation, with the timeline tracking cycle restoration. For readers actively trying to conceive: tracking ovulation via basal body temperature, ovulation predictor kits, or cycle tracking apps gives early information about whether ovulation has resumed. If cycles return but conception doesn’t happen within a reasonable timeframe, reproductive endocrinology evaluation is the appropriate next step. Age matters here: women in their early 30s and younger generally have more time to wait for spontaneous recovery; women in their late 30s and beyond may benefit from earlier specialist evaluation.
Pregnancy during recovery. This is specialist territory. ACOG Committee Opinion 711 and SAMHSA TIP 63 both recommend medication-assisted treatment (typically buprenorphine or methadone) for pregnant women with opioid use disorder, not abrupt cessation. ACOG’s language is direct: “opioid agonist pharmacotherapy is the recommended therapy and is preferable to medically supervised withdrawal because withdrawal is associated with high relapse rates, which lead to worse outcomes.” Maternal-fetal medicine and OB clinicians with substance-use experience should be involved. Pregnancy decisions in this context aren’t this page’s role; the point here is that the considerations are real and the appropriate routing is direct.
Perimenopausal and postmenopausal readers. The HPG axis effects of opioid use overlay onto a system already in transition. Disentangling opioid-related effects from natural perimenopausal changes (which include many of the same symptoms: irregular cycles, hot flashes, mood changes, sleep disruption) requires clinical evaluation. The Menopause Society (formerly NAMS) maintains a directory of MSCP-credentialed clinicians who can sort this picture.
Birth control during recovery. Hormonal contraceptives interact with the recovery picture in ways worth understanding. Combined oral contraceptives suppress the natural cycle, which can mask the recovery a reader is trying to track. Progestin-only methods affect mood for some users. IUDs minimize systemic hormone effects. The trade-offs are real; specific contraceptive choices during recovery are individual clinical decisions.
Hormone therapy when symptoms persist. Real options exist when persistent endocrine symptoms warrant clinical intervention. The landscape is genuinely individualized; the page describes that options exist and routes to clinicians with depth (reproductive endocrinology, Menopause Society clinicians, women’s-health specialists with substance-use experience).
Testing notes specific to women. Cycle-day timing matters because hormone levels vary across the menstrual cycle. ASRM specifies days 2 to 4 for baseline FSH and estradiol. Mid-luteal progesterone (about a week before expected next menses) confirms recent ovulation if > 3 ng/mL. Random-day testing gives much less useful information. Prolactin elevation is more clinically significant in women than men because it can affect both libido and menstrual function directly.
Finding the right kind of clinician. Generic primary care often defaults to “rule out pregnancy and prescribe birth control” without addressing the broader endocrine picture. Better fits: reproductive endocrinologists for fertility and persistent cycle issues, Menopause Society clinicians for perimenopausal women, women’s-health specialists with substance-use experience, and some telehealth providers who have explicitly handled kratom or 7-OH recovery.
The PAWS connection
The endocrine picture and the PAWS picture share substantial symptom overlap: low mood, fatigue, anhedonia, sleep disturbance, low libido. They are not separate conditions; they are connected, and recovery of both often runs together. Readers experiencing what they thought was “just PAWS” may benefit from getting endocrine testing as well, particularly if specific symptoms (libido, cycle disruption, body composition) have not improved with time. See What is PAWS for the broader symptom and timeline picture.
Where to read next
- What is PAWS: the broader symptom picture, the timeline, the neurobiology, and what else helps
- Long-Term Outlook: the multi-year recovery arc and what the literature actually shows
- Dopamine Recovery: reward-system recovery, which overlaps with the motivation and libido picture
- Depression and Anhedonia: the focused page on mood symptoms and clinical interventions
- Sleep Recovery: sleep architecture and what helps
- Tapering Off 7-OH: endocrine recovery often begins during taper, not after
- Helper Medications: prescription comfort meds with established evidence
- Telehealth Providers: clinicians who can order endocrine testing and arrange specialty referrals